Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life

BACKGROUND: The intravenous co-infusion of labradimil, a metabolically stable bradykinin B2 receptor agonist, has been shown to temporarily enhance the transvascular delivery of small chemotherapy drugs, such as carboplatin, across the blood-brain tumor barrier. It has been thought that the primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarin, Hemant, Kanevsky, Ariel S, Fung, Steve H, Butman, John A, Cox, Robert W, Glen, Daniel, Reynolds, Richard, Auh, Sungyoung
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689161/
https://www.ncbi.nlm.nih.gov/pubmed/19439100
http://dx.doi.org/10.1186/1479-5876-7-33

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689161/
https://www.ncbi.nlm.nih.gov/pubmed/19439100
http://dx.doi.org/10.1186/1479-5876-7-33

Ejemplares similares